The role of hyperglycemia in the development and progression of microvascular and macrovascular complications of type 2 diabetes has been amply substantiated in the literature. So too has the need to aggressively treat hyperglycemia, dyslipidemia, and hypertension in order to prevent or delay the progression of these complications. The following series of slides based on the results of landmark trials provide substantial evidence to support aggressive treatment.